Introduction
It is known that p53 tumor-suppressor protein has one of the principal roles in preventing cancer development in normal cells. The cellular response to p53 activation is determined by differential regulation of downstream target genes that direct toward cell cycle arrest, apoptosis or senescence. 1 The outcome of p53 activation leads to tumor suppression by impeding DNA damage, repairing damaged DNA or exterminating potentially oncogenic cells from the proliferating population. 2, 3 Overexpression of exogenous p53 is one of the strategies in cancer therapy because cancer cells are lacking in p53-dependent defensive mechanisms and have a higher sensitivity to exogenous p53. When the construct expressing wild-type p53 is introduced to cancer cells, downstream signaling evokes a massive suppressor effect on cell cycle and/or induction of apoptosis. 4 Some preclinical and clinical p53 gene therapy trials with favorable response are currently under way, [5] [6] [7] [8] [9] but more refinements are necessary.
For the evaluation and optimization of gene therapy, the ability to quantitatively and noninvasively monitor the location, magnitude and duration of transgene expression in vivo is critical. 10 The expression of a transferred gene in vivo can be visualized indirectly by using appropriate reporter gene imaging technology. 10, 11 Moreover, the development of customized gene transfer vectors will enhance the safety and efficiency of therapeutic gene expression in various settings of gene therapy protocol. Under certain circumstances, it is necessary to halt the expression of the introduced transgene, and especially when undesired adverse effects occur. On the other hand, it might be necessary to control transgene expression at a sustained level to obtain prolonged therapeutic effects. Considering these aspects, in p53 gene therapy, development of a novel gene transfer vector with controllable gene expression system coupled to a reporter gene that can be monitored simultaneously becomes important.
Moreover, noninvasive imaging-based assessment of therapeutic response and outcome of exogenous wildtype p53 gene transfer in tumor is of critical value, but it has been rarely reported. Positron emission tomography (PET) using fluoro-2-deoxy-D-glucose (FDG), a widely used PET tracer to measure glucose metabolism and assess conventional therapies, could also be applicable for monitoring tumor response to p53 gene therapy. of p53 in cellular and tumor glucose metabolism, with differential results. [13] [14] [15] In addition, some clinical studies with FDG-PET revealed the association between p53 and tumor glucose utilization measured by FDG uptake. [16] [17] [18] [19] Imaging of glucose utilization can provide a marker of metabolic changes during p53 therapy and may be used as a read-out for the effectiveness of therapy.
The aim of this study was to analyze controllable p53 transgene expression in real time and treatment response in a timely manner, using noninvasive imaging techniques. We constructed a doxycycline (tetracycline analog)-regulated bidirectional novel vector harboring a reporter gene encoding red fluorescence protein (RFP) and a tumor-suppressor protein (wild-type p53), and demonstrated their inducible, simultaneous and coordinated expression, p53 mediated-downstream signaling, and its effects both in vitro and in vivo. 
Results

Generation of doxycycline-controllable HEK293 cell line expressing RFP and wild-type p53
The HEK293-Tet-Off advanced cell line was transfected with doxycycline-regulated bidirectional TRE-tight vector harboring RFP and p53, and a stably transfected cell line was obtained by selection. Under the doxycycline (À) condition the fluorescence intensity emitted from established cell lines was strongly correlated with the cell number, which increased with time (R 2 ¼ 0.8634, 0.7907 and 0.7778 for 24, 48 and 72 h, respectively) (Figures 1a and b) .
Validation of concurrent and coordinated expression of RFP and p53 expression by western blotting Cells incubated in the doxycycline (À) medium showed significant increases of RFP, total p53 and activated p53 (p53 Ser 15 ) protein expression. Even a low dose of doxycycline (10 ng ml
À1
) tightly regulated the expression of the transgenes (Figure 2a) . Time-dependent increases in expressions were also observed (Figure 2b) . The correlation between RFP and p53 expression levels was validated, as strong correlations with total p53 (R 2 ¼ 0.9278) and activated p53 Ser 15 (R 2 ¼ 0.9705) were demonstrated (Figure 2c ).
Evaluation of activated p53-dependent downstream signaling by western blotting
After the cells were incubated with doxycycline (À) or (+) medium for 48 h, expression levels of p53-associated or -downstream proteins were compared. Stably transfected cells showed induced p53 overexpression, increased expression of activated p53 phosphorylated at serine 15, p21, Bax and MDM2 by the depletion of doxycycline, whereas the control cell line showed no obvious expression change of these proteins, indicating that transferred p53 has regulative activity for key downstream genes of apoptosis and cell cycle arrest (Figure 3a) . Quantification was achieved by normalization against actin. The fold increase over doxycycline (+) condition was shown with bar graphs for each protein (Figure 3b ). 
Evaluation of p53-mediated effects on tumor growth
Tumors of the doxycycline-untreated mice showed gradual decrease in volume compared with those of the doxycycline-treated group (Figure 5a ).
Verification of expression of transgenes regulated by doxycycline in vivo
When inoculated tumor masses had reached appropriate size, doxycycline was deleted from drinking water and ]FDG uptake ratios calculated from PET images were 1.06±0.12 and 1.13 ± 0.07 for p53 (+) tumor and 1.52 ± 0.03 and 1.81±0.06 for p53 (À) tumor, respectively. They fairly paralleled the results from the biodistribution study.
Discussion
We previously studied the pharmacological control of reporter gene expression in vivo and examined the correlation between PET image signal intensity and the fraction of cancer cells showing reporter transgene Controllable p53 transfer and tumor response imaging W Aung et al expression. 20 Sun et al. 21 also utilized the inducible bidirectional tetracycline-regulated vector system and confirmed the colocalization and coexpression of two reporter transgenes in the same tumor by PET imaging.
In this study, we established the doxycycline-regulated bidirectional gene expression vector harboring RFP reporter gene and wild-type p53 therapeutic gene, and stably transfected it to the HEK293-Tet-Off advanced cell line. Although the HEK293 cell line is non-neoplastic in cell origin, it was transformed by adenovirus 5 DNA and mimics some characteristics of cancer cells, at least uncontrolled growth. Also, this cell line provides an easy way for stable transfection and establishment of a xenograft tumor model. In the original HEK293 cell line, endogenous p53 was functionally stabilized due to the expression of transgenic adenoviral oncoproteins, 22 and thus baseline levels of endogenous p53 in acquired stable cell lines were thought to be the same.
Therewith, bidirectional vector-derived excessive exogenous p53 together with RFP expression and their activity in stable transfectants could be rationally evaluated. The establishment of the system was confirmed by in vitro experiments. The expression level of RFP was monitored by measuring fluorescence intensity both by in vitro and in vivo optical imaging. Western blot analysis verified the simultaneous and coordinated expression of reporter and functional therapeutic proteins. The active p53 function was checked with in vitro tests such as western blot analysis, apoptosis detection, cellular growth assay, colony formation assay and in vivo tumor growth assay. In addition, we performed in vitro radioisotope uptake assay, in vivo PET imaging and biodistribution study to measure FDG uptake, providing evidence for the feasibility of FDG-PET as a tool for assessing the therapeutic response in p53 cancer therapy. 
Ideally, as a safe and efficient gene therapy vector, therapeutic gene expression should be robust, but controllable. In our model, by the removal of doxycycline exposure to stable transfectant, therapeutic wild-type p53 expression and activation were vigorously increased. This aberrant expression of p53 upregulated Bax and p21, pivotal genes involved in apoptosis and cell cycle progression, respectively. p53 induced its negative regulator MDM2, 23 which in turn inhibited p53-mediated transactivation 24 and targeted p53 degradation by the ubiquitin-mediated proteolysis pathway. 25 However, it seemed that the elevated level of MDM2 did not parallel the increased level of wild-type p53, and its activity for feedback regulation of the p53-MDM2 interaction was not sufficient. Moreover, it has been reported that interfering with the interaction between p53 and MDM2 leads to accumulation of p53 protein and the subsequent initiation of p53-dependent processes such as transactivation, cell cycle arrest or apoptosis. 26 In this regard, we also found increased p53 phosphorylation at serine 15 position, one of the key initiating events for p53 transactivation, by attenuating the p53-MDM2 interaction. 27, 28 According to our results, under the doxycycline (+) condition, both stably transfected cells and the control cells (mock transfected) showed identical characters in respect to cell growth rate, colony-forming property and tumor growth rate, whereas under the doxycycline (À) condition, cells with induced p53 overexpression showed not only a more apoptotic tendency but also significantly decreased growth rate and colony formation.
The fluorescence intensity emitted by reporter RFP was well correlated with the cell number in the in vitro experiment. But in an animal model, fluorescence intensity did not have strong correlation with tumor volume. Nevertheless, RFP gene expression was a good marker for investigating the dynamics of regulated gene expression or for indirectly monitoring the presence or absence of target p53 gene expression regulated by drug in drinking water, and effectively assisted rapid and easy confirmation in tumor without the necessity for radiotracers.
Viral-and nonviral-mediated p53 gene therapy was tested in various in vivo tumor models, and several clinical trials have been performed with different therapeutic protocols. 9, 8 Nonetheless, still more efforts were needed in the approach toward desired therapeutic achievements. One of the obstacles to the clinical translation of p53 gene therapy protocols was the insufficient knowledge related to the feasibility of monitoring early responses to such therapies with clinically applicable and commercially available molecular imaging agents, such as [ Controllable p53 transfer and tumor response imaging W Aung et al to evaluate response to radio-and chemotherapy 29, 30 and to predict the outcome of therapy, as a decrease in FDG tumor uptake can indicate a positive response to treatment, 31, 32 its application in gene therapy is rarely reported. 12 Schwartzenberg-Bar-Yoseph et al. 33 have reported that wild-type p53 downregulates the gene expression of glucose transporters GLUT-1 and GLUT-4 in a tissuespecific manner. Differences in tumor glucose metabolism seen in therapeutic gene-transduced cells and nontransduced cells may be indicative of early responses to therapy and should be thoroughly investigated. For this purpose, in this study we assessed the efficacy of [ It will be useful to modify treatment protocol to achieve maximum therapeutic effect or to change to alternative treatment regimens at a very early stage.
In conclusion, in our preclinical model, an optical imaging approach provided indirect confirmation of the location and real-time persistence of transferred and induced expression of therapeutic gene p53, and its comprehensive biological response in tumor could be predicted with FDG-PET imaging. Thus, integration of the two molecular imaging metrics, coupling with bidirectional vector, may provide improved interpretation of therapeutic responses and thus allow optimization of novel therapeutic strategies. Our study model was dedicated to a simple and straightforward understanding of regulable p53 tumor therapy and the feasibility of assessing its therapeutic response on PETimaging. For practical application in a clinical setting, more novel construct designs and outstanding gene transfer methods still need to be developed. 
Materials and methods
Cell line and culture condition HEK293-Tet-Off Advanced cell line expressing the tetracycline-controlled transactivator (tTA-Advanced) was purchased from Clontech (Palo Alto, CA, USA) and cultivated at 37 1C in a humidified atmosphere containing 5% CO 2 in Dulbecco's modified Eagle's medium (Sigma, St Louis, MO, USA) supplemented with 10% Tet system-approved fetal bovine serum (Clontech, Mountain View, CA, USA), 4 mM L-glutamine, 100 mg ml À1 G418 (Roche, Basel, Switzerland), 100 U ml À1 penicillin-G sodium and 100 mg ml À1 streptomycin sulfate (Invitrogen, Carlsbad, CA, USA).
Construction of plasmid and transfection
pTRE-Tight-BI-DsRed-Express vector, a bidirectional TRE-Tight plasmid that can be used to express RFP (DsRed-express) along with a gene of interest, and pCMV-p53 expressing the wild-type 53 tumor suppressor protein, were purchased from Clontech. Wild-type p53 fragment was excised out by using HindIII and EcoRI and inserted into the multiple cloning sites of pTRETight-BI-DsRed-Express vector. Then, HEK 293-Tet-Off Advanced cell line was co-transfected with established plasmid or original pTRE-Tight-BI-DsRed-Express plasmid and hygromycin marker (Clontech). Lipofectamine LTX reagent (Invitrogen) was used following the protocol recommended by the manufacturer. The original plasmid was used to establish a control cell line. Stably transfected cell line was obtained by selection with 400 mg ml À1 hygromycin B (Invitrogen). Single cellderived clones of transfected cells showing high expression of RFP in the absence of doxycycline (Clontech), checked using Olympus FV1000 fluorescence microscope (Olympus, Tokyo, Japan), were selected and propagated further in medium containing 500 ng ml À1 doxycycline.
In vitro fluorescence imaging
Cells at various concentrations (6.25, 12.5 and 25 Â 10 4 cells per well) were seeded in collagen-coated EZView LB 24-well plates (IWAKI, Tokyo, Japan) with doxycycline (À) medium for 24 h. Then, the fluorescence intensity emitted from cells was measured by IVIS lumina optical imaging system (Xenogen, Alameda, CA, USA) for 3 consecutive days. Just before measurement, the medium was changed with phenol red-free HBSS. We used the filter set for DsRed (excitation: 500-550 nm, emission: 575-650 nm, background excitation: 460-490 nm) and set the constant imaging parameters (exposure time: 2 s, binning: medium, lens aperture (f/stop): 2, field of view: 10 cm, floor lamp level: high). To obtain the autofluorescent-corrected image, the background filter image was subtracted from the primary excitation filter image using the Image Math tool and appropriate scale factor, according to the Living Image software version 2.6 (Xenogen) manual, and fluorescence intensity was measured as photons per second.
Western blot analysis
At the indicated time, cell lysates were prepared by cell lysis solution of Mammalian cell lysis kit (Sigma) and total protein was measured by DC protein assay kit (Bio-Rad, Hercules, CA, USA). Twenty micrograms of the protein was separated on a 5-12.5% polyacrylamide gel and transferred to Immobilon-P membrane (Millipore, Billerica, MA, USA). The membranes were then blocked by TBS BLOTTO A (Santa Cruz Biotechnology, Santa Cruz, CA, USA) at room temperature for 2 h and incubated with primary antibody at room temperature for 2 h. As primary antibodies, rabbit anti-DsRed antibody (Clontech), mouse anti-human p53 (DO-1) antibody (Santa Cruz Biotechnology), rabbit anti-phospho -p53 antibody (R&D Systems, Minneapolis, MN, USA), rabbit anti-human p21 (C-19) antibody, mouse antihuman Bax (2D2) antibody, mouse anti-human MDM2 (SMP14) antibody, and goat anti-human Actin (C-11) antibody (Santa Cruz Biotechnology) were used. After incubating with each primary antibody, the membranes were washed three times with TBS containing 0.05% Tween 20 and incubated with an anti-mouse, anti-rabbit (GE Healthcare UK, Little Chalfont, UK), or anti-goat IgG conjugated with horseradish peroxidase (Santa Cruz Biotechnology) corresponding to the type of primary antibody. To detect the protein level in the same membranes, stripping and incubation with each dedicated antibody were repeatedly carried out for one protein after another. After exposing the membranes to enhanced chemiluminescence plus western blotting detection system (GE Healthcare), images were obtained by Chemi-Smart 5000 (Vilber Lourmat, Marne-la-Vallée, France). Quantification was achieved by band densitometry using ImageJ 1.41o software (NIH, Bethesda, MD, USA) and normalized against the actin levels for evaluation.
Detection of apoptosis
Stably transfected cells were seeded in 35-mm glassbottom dishes (1 Â 10 5 /dish) in medium with or without doxycycline. After 48 h, medium was discarded and attached cells were washed with phosphate-buffered saline and fixed in 4% paraformaldehyde for 10 min at room temperature. Then cells were stained with Hoechst reagent (1 mg ml À1 ) (Invitrogen) at room temperature for 10 min, washed with phosphate-buffered saline and examined using Olympus FV1000 confocal laser microscopy (Olympus) with respective excitation and emission filters for Hoechst dye and RFP (DsRed).
Cell growth assay
Cells were plated in 35-mm dishes (5 Â 10 4 /dish) in medium with or without doxycycline. They were cultured in an incubator and the number of viable cells was counted at the indicated times (n ¼ 3 per time) using a hemocytometer.
Colony-forming assay
Using growth medium with or without doxycycline, stable cell lines were seeded in six-well plates (1000 cells per well). After 14 days of incubation, cells were fixed and stained with crystal violet. Colonies containing 450 cells were counted, and the mean plating efficiencies were determined and normalized to those of the doxycycline (+) condition.
Development of animal tumor model
All animal model experiments were carried out in accordance with the guidelines for animal experimentation determined by the Institutional Animal Care and 7 in 100 ml culture medium) were mixed with 100 ml of phenol red-free BD Matrigel Matrix (BD Biosciences, Bedford, MA, USA) and subcutaneously inoculated into the flank of nude mice (8-to 9-week-old females, BALB/cA Jcl-nu/nu mice; CLEA, Japan).
In vivo tumor growth study
To compare the growth rate between tumors overpressing p53 or not, mice were initially administered drinking water containing doxycycline (500 mg ml
À1
) for at least 3 days, and then implanted with the stably transfected cells mentioned above. When the tumor masses had reached diameters 45 mm, mice were divided into two groups; one group was continuously administered the doxycycline-containing water and the other was administered normal drinking water. Gross appearance and tumor growth were monitored by caliper measurements every 2 days. Tumor volume was estimated as V (mm 
In vivo fluorescence imaging
For fluorescence imaging of in vivo tumors, mice-bearing xenograft tumors were anesthetized by inhalation of 2.5% isoflurane and images were acquired by the same setting used for in vitro fluorescence imaging except that the field of view was changed to 12.5 cm. For quantitative analysis, regions of interest were encircled by hand over the tumors, and fluorescence intensity was measured as photons per second with the above-mentioned software. 
Radiochemicals
Radiolabeled FDG uptake assay
Using growth medium with or without doxycycline, stable transfectants were seeded in 12-well plates (2.5 Â 10 5 per well). Forty-eight hours after plating, incubation medium was replaced with freshly prepared medium containing radiotracer [
14 C]FDG (3.7 kBq ml
À1
). One hour after incubating with radiotracer, the cells were washed twice with cold phosphate-buffered saline and lysed with 100 ml of 0.2 N NaOH solution. Then, 50 ml of cell lysates mixed with 6 ml of liquid scintillator fluid (Hionic-Fluor, PerkinElmer, Waltham, MA, USA) was used for cell lysate radioactivity measurement by liquid scintillation analyzer Tri-Carb 3100TR (PerkinElmer, Downers Grove, IL, USA) by appropriate protocol. The protein concentration of the cell lysates was measured with Quick Start Bradford protein assay reagent (Bio-Rad).
In vivo biodistribution with radiolabeled FDG Doxycycline-treated and untreated mice were regularly monitored with IVIS imaging system for 14 days to identify p53 expression induced in tumor. Mice were fasted overnight and then intravenously injected with the radiotracer [ 18 F]FDG (3.7 MBq) through the tail vein. Fifty minutes later, mice were killed and approximately 100 mg of each tissues of interest was excised. Whole bodies and tissue samples were weighed, and their radioactivities were measured by auto well gamma counter (WIZARD, PerkinElmer). Radioactivity uptake in the tumor and tissues of interest was expressed by standardized uptake values (SUVs). The tumor-to-lung, tumor-to-liver and tumor-to-blood ratios were calculated using SUVs. F]FDG (7.4 MBq) through the tail vein. Fifty minutes after injection, PET data acquisition was conducted for 10 min using a smallanimal PET system (Inveon, Siemens Medical Solutions, Malvern, PA, USA) under 1.5-2% isoflurane anesthesia during the entire scanning period. Mice were heated by lamp during the PET scan to maintain body temperature. Images were reconstructed using filtered back projection (ramp filter with a cutoff frequency of 0.5) without attenuation correction using Inveon Acquisition Workplace software (Siemens Medical Solutions). Tracer uptake was quantified as SUVs. Regions of interest were manually drawn on three slices each of tumor, lung and liver, and SUVmean in each regions of interest was measured. Then, tumor-to-lung and tumor-to-liver uptake ratios were calculated using the three SUVmean values. To obtain the relevant anatomical information, right after PET scanning, mice fixed in the same bedposition were transported to an undocked CT scanner and scanned with CT operation mode (Siemens Medical Solutions). CT images were reconstructed using Inveon Acquisition Workplace software (Siemens Medical Solutions). Both the PET and CT data sets were imported, and fused images were obtained using ASIPro VM software (CTI Concorde Microsystems, Knoxville, TN, USA).
Statistical analysis
Significance of differences was determined by Student's t-test. P-values less than 0.05 were considered to be significant.
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